CSCIED

期刊目次

加入编委

期刊订阅

添加您的邮件地址以接收即将发行期刊数据:

Open Access Article

International Journal of Clinical Research. 2026; 10: (7) ; 143-145 ; DOI: 10.12208/j.ijcr.20260358.

Study on the impact of helicobacter pylori eradication therapy on pathological improvement of gastric mucosa in patients with chronic gastritis
幽门螺杆菌根除治疗对慢性胃炎患者胃黏膜病理改善影响研究

作者: 李露 *, 陈建鹏, 刘自力, 郭娟

新疆生产建设兵团第五师医院 新疆博乐

*通讯作者: 李露,单位:新疆生产建设兵团第五师医院 新疆博乐 ;

发布时间: 2026-07-22 总浏览量: 25

摘要

目的 研究幽门螺杆菌(Hp)根除治疗对慢性胃炎患者胃黏膜病理改善影响。方法 选取2024年3月-2025年10月本院84例慢性胃炎患者,以随机数字表法分组,各42例。对照组采取常规治疗,研究组采取Hp根除治疗。对比临床疗效。结果 胃黏膜炎症评分、胃黏膜萎缩及肠上皮化生评分等指标比较,研究组优于对照组(P<0.05);不良反应两组比较差异无显著性(P>0.05)。结论 Hp根除治疗可有效改善慢性胃炎患者胃黏膜炎症状态,促进萎缩逆转,且安全性良好。

关键词: 慢性胃炎;幽门螺杆菌;根除治疗;肠上皮化生;胃黏膜萎缩

Abstract

Objective To investigate the effect of eradicating Helicobacter pylori (Hp) on the pathological improvement of gastric mucosa in patients with chronic gastritis.
Methods 84 patients with chronic gastritis in our hospital from March 2024 to October 2025 were selected and divided into two groups using a random number table method, with 42 patients in each group. The control group received conventional treatment, while the study group received Hp eradication treatment. Compare clinical efficacy.
Results The comparison of indicators such as gastric mucosal inflammation score, gastric mucosal atrophy, and intestinal metaplasia score showed that the study group was superior to the control group (P<0.05); There was no significant difference in adverse reactions between the two groups (P>0.05).
Conclusion   Hp eradication therapy can effectively improve the inflammatory state of gastric mucosa in patients with chronic gastritis, promote atrophy reversal, and has good safety.

Key words: Chronic gastritis; Helicobacter pylori; Eradication therapy; Intestinal metaplasia; Gastric mucosal atrophy

参考文献 References

[1] 杨亚莉,张志强,魏毅强,等.荆花胃康胶丸联合益生菌治疗胃幽门螺杆菌阳性慢性胃炎及对胃幽门螺杆菌根除率的效果[J].西北药学杂志,2023,38(3):167-171.

[2] 李晶洁,齐蕊,吕书勤.活血解毒汤对幽门螺杆菌感染慢性萎缩性胃炎患者胃黏膜微观征象及炎症状态的影响[J].现代中西医结合杂志,2023,32(22):3130-3134.

[3] 刘倩,苏卫仙,杜丙杰,等.荜铃胃痛颗粒联合四联疗法治疗幽门螺杆菌相关慢性胃炎的疗效及对患者生活质量的改善[J].河北中医,2025,47(7):1089-1093.

[4] 田求明,袁芳琳.三联疗法联合替普瑞酮治疗对慢性浅表性胃炎患者幽门螺杆菌根除率的影响[J].现代诊断与治疗,2024,35(7):986-988.

[5] 黄少云.胃复春联合叶酸与幽门螺杆菌根除治疗幽门螺杆菌阳性慢性萎缩性胃炎的效果探讨[J].现代医学与健康研究电子杂志,2025,9(11):24-27.

[6] 犹敦江.幽门螺杆菌根除性治疗联合益生菌在慢性胃炎患者中的应用效果[J].中外医药研究,2024,3(28):57-59.

[7] 寇虎红.抗幽合剂联合四联疗法对慢性胃炎合并幽门螺杆菌阳性患者根除率的影响分析[J].甘肃科技,2023, 39(4):79-81.

[8] 尚超辉,陈策,何敬堂.益生菌联合铋剂四联治疗幽门螺杆菌相关性慢性胃炎的效果评价[J].现代医学与健康研究电子杂志,2024,8 (16):27-30.


引用本文

李露, 陈建鹏, 刘自力, 郭娟, 幽门螺杆菌根除治疗对慢性胃炎患者胃黏膜病理改善影响研究[J]. 国际临床研究杂志, 2026; 10: (7) : 143-145.